SomantiX is a Dutch biotech company that aims to select and validate targets for tumor vessel directed cancer therapy. These targets will qualify for development of binders that will be used for therapeutic and diagnostic applications. Using EdgeLeap’s cutting edge data integration and mining technology, SomantiX will add value to their exclusive list of potential tumor vessel targets that have been identified through screening and differential expression analysis of tumor and normal tissues. Read more here.
EdgeLeap joins forces with SomantiX B.V. to select new targets for cancer therapy.